Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma

Main Article Content

Georgina V Long
Axel Hauschild
Mario Santinami
Victoria Atkinson
Mario Mandala
Vanna Chiarion-Sileni
James Larkin
Marta Nyakas
Caroline Dutriaux
Andrew Haydon
Caroline Robert
Laurent Mortier
Jacob Schachter
Dirk Schadendorf
Thierry Lesimple
Ruth Plummer
Ran Ji
Pingkuan Zhang
Bijoyesh Mookerjee
Jeff Legos
Richard Kefford
Reinhard Drummer
John M Kirkwood

Keywords

melanoma, genetics, dabrafenib, trametinib

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Novartis.

 

Copyright 2018 SKIN

Article Sidebar

Poster PDF
Published
Feb 23, 2018
DOI https://doi.org/10.25251/skin.2.supp.43

Article Details

How to Cite
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Drummer, R., & Kirkwood, J. M. (2018). Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma. SKIN The Journal of Cutaneous Medicine, 2(S1), S43. https://doi.org/10.25251/skin.2.supp.43
Issue
Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Section
Melanoma
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>